{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(21)"],"submitter":["Mahana I"],"pubmed_abstract":["<h4>Background</h4>Our objective was to assess real-world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy.<h4>Methods</h4>We used the Symphony Dataverse to study patients receiving mavacamten between May 25, 2022 and June 30, 2024. Safety outcomes were prespecified.<h4>Results</h4>We included 2440 patients and 18 494 mavacamten dispenses (63% women, median age 66 years [interquartile range {IQR}, 55-73]). Patients were followed for a median of 3037.0 days (IQR, 2808-3221) before mavacamten initiation and for 240 days (IQR, 117-407) on mavacamten. Atrial fibrillation or flutter (AF/AFL) at baseline were present in 536 (22%) of patients, whereas new-onset AF/AFL requiring therapy occurred in 125 patients (5%) and"],"journal":["Journal of the American Heart Association"],"pagination":["e042488"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12684520"],"repository":["biostudies-literature"],"pubmed_title":["Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy."],"pmcid":["PMC12684520"],"pubmed_authors":["Mahana I","Kamna D","Nguyen O","Masri A","Elman MR","Chen H","Mejia AT","Volk H"],"additional_accession":[]},"is_claimable":false,"name":"Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy.","description":"<h4>Background</h4>Our objective was to assess real-world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy.<h4>Methods</h4>We used the Symphony Dataverse to study patients receiving mavacamten between May 25, 2022 and June 30, 2024. Safety outcomes were prespecified.<h4>Results</h4>We included 2440 patients and 18 494 mavacamten dispenses (63% women, median age 66 years [interquartile range {IQR}, 55-73]). Patients were followed for a median of 3037.0 days (IQR, 2808-3221) before mavacamten initiation and for 240 days (IQR, 117-407) on mavacamten. Atrial fibrillation or flutter (AF/AFL) at baseline were present in 536 (22%) of patients, whereas new-onset AF/AFL requiring therapy occurred in 125 patients (5%) and","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-05T23:55:26.97Z","creation":"2026-05-23T03:13:48.033Z"},"accession":"S-EPMC12684520","cross_references":{"pubmed":["41147368"],"doi":["10.1161/JAHA.125.042488"]}}